Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTV01E-2 Immunogenicity and Safety in Previously Vaccinated Population
NCT05933512Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of SCTV01E-2 in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Status: unknown.
02
Drugs
SCTV01E-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05933512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933512.